Literature DB >> 34189816

Mean macular intercapillary area in eyes with diabetic macular oedema after anti-VEGF therapy and its association with treatment response.

Osama A Sorour1,2, Mohamed Elsheikh3,4, Siyu Chen5, Ayman G Elnahry6, Caroline R Baumal2, Varsha Pramil2, Tamer I Abdelhalim1, Elsayed Nassar1, Eric M Moult5, Andre J Witkin2, Jay S Duker2, Nadia K Waheed2.   

Abstract

BACKGROUND: To evaluate the changes in the mean macular intercapillary area (ICA) from sequential enface optical coherence tomography angiography (OCTA) images following intravitreal anti-VEGF therapy in initially treatment-naïve eyes with diabetic macular oedema (DME).
METHODS: In this multicenter retrospective study, 6x6 and 3x3 mm customized, total retinal projection enface OCTA images were collected and processed for quantitative assessment of ICA by a customized MATLAB software. Measurements were done in concentric regions centered on the fovea -with the exclusion of foveal avascular zone (FAZ)- in 0.5 mm diameter increments as well as within the intervening rings.
RESULTS: 6x6 mm OCTA images from 46 eyes of 29 patients, and 3x3 mm OCTA images from 23 eyes of 15 patients were included in this study. There was no significant change in mean ICA after treatment in either scan size or in any measurement regions (all p > 0.05). Multivariate analysis revealed that baseline BCVA was significantly correlated with the visual outcome (p = 0.039). Additionally, after correction for age, baseline central retinal thickness (CRT), baseline BCVA, and retinopathy severity, mean ICA in the 1.5 mm circle was found to be a significant predictor of post treatment CRT, (p = 0.006).
CONCLUSIONS: Absence of significant change in mean ICA after a minimum of three intravitreal anti-VEGF injections, may indicate that, in the short term, anti-VEGF injections neither impair nor improve macular perfusion in DME. Baseline BCVA was found to be a robust predictor of functional outcome, while inner mean ICA was a significant predictor for macular thickness outcomes. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  Diabetic macular oedema; OCT; anti-VEGF; diabetic retinopathy; intravitreal

Year:  2021        PMID: 34189816     DOI: 10.1111/ceo.13966

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  5 in total

1.  Comment on: Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy.

Authors:  Ayman G Elnahry; Wael A Yussuf
Journal:  Eye (Lond)       Date:  2021-10-06       Impact factor: 4.456

2.  OCT-Angiography Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Dexamethasone Implant.

Authors:  Pablo Carnota-Méndez; Carlos Méndez-Vázquez; Conchi Pérez-Gavela
Journal:  Clin Ophthalmol       Date:  2022-02-02

3.  Application of Improved U-Net Convolutional Neural Network for Automatic Quantification of the Foveal Avascular Zone in Diabetic Macular Ischemia.

Authors:  Yongan Meng; Hailei Lan; Yuqian Hu; Zailiang Chen; Pingbo Ouyang; Jing Luo
Journal:  J Diabetes Res       Date:  2022-02-26       Impact factor: 4.011

4.  Optical Coherence Tomography Angiography Biomarkers Predict Anatomical Response to Bevacizumab in Diabetic Macular Edema.

Authors:  Ayman G Elnahry; Alia M Noureldine; Ahmed A Abdel-Kader; Osama A Sorour; David J Ramsey
Journal:  Diabetes Metab Syndr Obes       Date:  2022-02-09       Impact factor: 3.168

5.  Microvascular Changes After Conbercept Intravitreal Injection of PDR With or Without Center-Involved Diabetic Macular Edema Analyzed by OCTA.

Authors:  Wei Lin; Meng Feng; Tingting Liu; Qingxu Wang; Wenqi Wang; Xiao Xie; Wenhao Li; Jitian Guan; Zhongyu Ma; Tong Liu; Qingjun Zhou
Journal:  Front Med (Lausanne)       Date:  2022-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.